AEs reported by âĽ3 patients in the Japan+Korea cohort of any relevant treatment arm and the corresponding incidence in the Not-Japan+Korea cohort and the Overall population (Safety population). (DOCX 26.9 KB
Scoring for severity of asthma modified by Eisnerâs method. Table S2: Pearson correlation coeffici...
Sensitivity analysis after including all patient-years with no history of asthma related healthcare ...
Scatter plot of ACQ and miniAQLQ scores. Table S1. Characteristics of asthma. Table S2. Lung functio...
Region ratios of ‘treatment effect’ in Japan+Korea and Not-Japan+Korea patients, where ‘treatment ef...
Adjusted treatment differences from baseline in trough FEV1 at Week 12 (Efficacy population). (DOCX ...
Profile of the three Phase III studies included in both the efficacy and safety analyses. (DOCX 47.4...
Profile of the two additional Phase IIb studies included in only the safety analyses. (DOCX 25.6 KB
List of Institutions and Independent Ethics Committees/Institutional Review Boards for Studies HZA10...
Summary of the most common adverse events (âĽ5%) in the Asian and non-Asian populations. (DOCX 24 k...
Asthma quality of life questionnaire score (pooled data) in Asian and non-Asian patients, at baselin...
e-table 1: Characteristics of the studies and treatment arms included in the MTC. e-table 2: Results...
Flowchart of the study population. Detailed information on characteristics and co-medication of case...
Supplementary appendix: The anti-inflammatory duration of action of fluticasone furoate/vilanterol t...
Additional results for patient demographics and baseline characteristics, exacerbation rates, exacer...
Table S1. The Severity Scale of asthma patients in the Guidelines for Prevention and Treatment of Br...
Scoring for severity of asthma modified by Eisnerâs method. Table S2: Pearson correlation coeffici...
Sensitivity analysis after including all patient-years with no history of asthma related healthcare ...
Scatter plot of ACQ and miniAQLQ scores. Table S1. Characteristics of asthma. Table S2. Lung functio...
Region ratios of ‘treatment effect’ in Japan+Korea and Not-Japan+Korea patients, where ‘treatment ef...
Adjusted treatment differences from baseline in trough FEV1 at Week 12 (Efficacy population). (DOCX ...
Profile of the three Phase III studies included in both the efficacy and safety analyses. (DOCX 47.4...
Profile of the two additional Phase IIb studies included in only the safety analyses. (DOCX 25.6 KB
List of Institutions and Independent Ethics Committees/Institutional Review Boards for Studies HZA10...
Summary of the most common adverse events (âĽ5%) in the Asian and non-Asian populations. (DOCX 24 k...
Asthma quality of life questionnaire score (pooled data) in Asian and non-Asian patients, at baselin...
e-table 1: Characteristics of the studies and treatment arms included in the MTC. e-table 2: Results...
Flowchart of the study population. Detailed information on characteristics and co-medication of case...
Supplementary appendix: The anti-inflammatory duration of action of fluticasone furoate/vilanterol t...
Additional results for patient demographics and baseline characteristics, exacerbation rates, exacer...
Table S1. The Severity Scale of asthma patients in the Guidelines for Prevention and Treatment of Br...
Scoring for severity of asthma modified by Eisnerâs method. Table S2: Pearson correlation coeffici...
Sensitivity analysis after including all patient-years with no history of asthma related healthcare ...
Scatter plot of ACQ and miniAQLQ scores. Table S1. Characteristics of asthma. Table S2. Lung functio...